Macquarie Group LTD Pro Qr Therapeutics N.V. Transaction History
Macquarie Group LTD
- $79.1 Billion
- Q2 2025
A detailed history of Macquarie Group LTD transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Macquarie Group LTD holds 620,000 shares of PRQR stock, worth $1.73 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
620,000
Previous 620,000
-0.0%
Holding current value
$1.73 Million
Previous $824,000
53.4%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PRQR
# of Institutions
64Shares Held
41.2MCall Options Held
26KPut Options Held
0-
Adage Capital Partners Gp, L.L.C. Boston, MA6.6MShares$18.4 Million0.02% of portfolio
-
Privium Fund Management B.V.5MShares$13.9 Million2.17% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.5MShares$9.76 Million1.2% of portfolio
-
Morgan Stanley New York, NY3.08MShares$8.6 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY2.08MShares$5.79 Million2.02% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $199M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...